FOXO4-DRI vs GlyNAC
A side-by-side research comparison of FOXO4-DRI and GlyNAC across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | GlyNAC |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Glycine + N-Acetylcysteine |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | OTC supplement combination |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Glycine and NAC (a cysteine donor) are the rate-limiting precursors for glutathione. Replenishing both restores intracellular glutathione, lowers oxidative stress, improves mitochondrial fuel oxidation, and reduces inflammation and insulin resistance. |
| Molecular weight | ~4,500 Da | Glycine 75.07 Da / NAC 163.19 Da |
| Half-life | 12-24 hours (D-amino acid stability) | Glycine ~1 h; NAC ~6 h |
| Bioavailability | Moderate (SubQ) | Glycine high; NAC ~4-10% but effective as cysteine donor |
| Typical dose | 5-10 mg/kg (animal studies) | Glycine ~100 mg/kg + NAC ~100 mg/kg per day |
| Frequency | 3x per week for 3 weeks | Split 1-2x daily |
| Route | Subcutaneous | Oral (powder or capsule) |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
GlyNAC reported benefits
- Restores glutathione levels
- Improves mitochondrial function
- Lowers oxidative stress and inflammation
- Better insulin sensitivity
- Improved strength and cognition (elderly)
- Sleep support (glycine)
Related comparisons
Research and educational reference only. Not medical advice.